VNDA|Vanda Pharmaceuticals Inc|Preço:6.280|Var. %:-0.11

Mais detalhes de Vanda Pharmaceuticals Inc Empresa

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Informações de Vanda Pharmaceuticals Inc



Código da empresaVNDA

Nome da EmpresaVanda Pharmaceuticals Inc

Data de listagemApr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

Número de funcionários368

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 12

EndereçoSuite 300E

CidadeWASHINGTON

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal20037

Telefone12027343400

Sitehttps://www.vandapharma.com/

Código da empresaVNDA

Data de listagemApr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

Executivos da empresa Vanda Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

1.59M

-70.28%

Mr. Gunther Birznieks

Senior Vice President - Business Development

204.77K

-141.34%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

--

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

122.59K

-236.09%

Ms. Anne Sempowski Ward

Independent Director

119.07K

--

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

--

Dr. Tage Honore, Ph.D.

Independent Director

86.87K

-7.60%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

--

Ms. Phaedra S. Chrousos

Independent Director

--

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

1.59M

-70.28%

Mr. Gunther Birznieks

Senior Vice President - Business Development

204.77K

-141.34%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

--

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

122.59K

-236.09%

Ms. Anne Sempowski Ward

Independent Director

119.07K

--

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Fanapt

117.30M

54.28%

Hetlioz

71.43M

33.05%

PONVORY

27.37M

12.67%

Por RegiãoUSD

Nome

Receita

Proporção

United States

216.10M

100.00%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Fanapt

117.30M

54.28%

Hetlioz

71.43M

33.05%

PONVORY

27.37M

12.67%

Distribuição de ações

Atualizado em: qua, 13 de mai

Investidores

Tipos de investidores

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

8.93%

Renaissance Technologies LLC

5.62%

State Street Investment Management (US)

5.01%

Vanguard Capital Management, LLC

4.13%

Acadian Asset Management LLC

4.01%

Outro

72.29%

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

8.93%

Renaissance Technologies LLC

5.62%

State Street Investment Management (US)

5.01%

Vanguard Capital Management, LLC

4.13%

Acadian Asset Management LLC

4.01%

Outro

72.29%

Tipos de investidores

Investidores

Proporção

Investment Advisor

28.54%

Investment Advisor/Hedge Fund

24.28%

Hedge Fund

13.25%

Individual Investor

6.16%

Private Equity

3.33%

Research Firm

2.13%

Pension Fund

0.55%

Bank and Trust

0.17%

Family Office

0.05%

Outro

21.54%

Participação acionária institucional



Atualizado em: qua, 1 de abr

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2026Q1

353

47.15M

78.40%

-5.25M

2025Q4

346

45.82M

77.53%

-10.46M

2025Q3

373

46.45M

78.60%

-9.99M

2025Q2

417

50.75M

85.90%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

5.37M

9.09%

-401.50K

-6.95%

Dec 31, 2025

Renaissance Technologies LLC

3.38M

5.72%

-95.96K

-2.76%

Dec 31, 2025

State Street Investment Management (US)

1.26M

2.14%

-7.54K

-0.59%

Dec 31, 2025

Acadian Asset Management LLC

2.41M

4.08%

+181.67K

+8.15%

Dec 31, 2025

Two Sigma Investments, LP

2.03M

3.43%

+456.69K

+29.06%

Dec 31, 2025

AIGH Capital Management, LLC.

1.46M

2.46%

+1.46M

--

Dec 31, 2025

Dimensional Fund Advisors, L.P.

2.12M

3.58%

-445.54K

-17.38%

Dec 31, 2025

Millennium Management LLC

1.68M

2.84%

-1.57M

-48.35%

Dec 31, 2025

BlackRock Financial Management, Inc.

1.62M

2.74%

-628.02K

-27.94%

Dec 31, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

iShares Neuroscience and Healthcare ETF

0.49%

Invesco NASDAQ Future Gen 200 ETF

0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.12%

ALPS Medical Breakthroughs ETF

0.1%

Federated Hermes MDT Small Cap Core ETF

0.09%

iShares Micro-Cap ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Franklin US Small Cap Multifactor Index ETF

0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

0.03%

Ver Mais

iShares Neuroscience and Healthcare ETF

Proporção0.49%

Invesco NASDAQ Future Gen 200 ETF

Proporção0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

Proporção0.12%

ALPS Medical Breakthroughs ETF

Proporção0.1%

Federated Hermes MDT Small Cap Core ETF

Proporção0.09%

iShares Micro-Cap ETF

Proporção0.05%

ProShares Ultra Nasdaq Biotechnology

Proporção0.04%

Franklin US Small Cap Multifactor Index ETF

Proporção0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporção0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

Proporção0.03%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados